. . . "An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180)"@en . "Penthrane"@en . . . . " "@en . . . . . . "Methoflurane"@en . . . "Methoxyfluranum"@en . . "approved"@en . . "Humans and other mammals"@en . . . . . "Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca²⁺ activated potassium channel, the glutamate receptor and the glycine receptor."@en . . "Methoxyfluran"@en . . "Methoxyflurane"@en . . . . . . . "Metoxiflurano"@en . . . . . . . . . "Methoxyfluoran"@en . . "Methyl 1,1-difluoro-2,2-dichloroethyl ether"@en . . . . . . "76-38-0"@en . . "LD₅₀=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage."@en . "For use in the induction and maintenance of general anesthesia"@en . .